Navigation Links
The FSH Society Issues Research Grant for Developing New Facioscapulohumeral Dystrophy Muscular Measurement Tool
Date:8/6/2013

Lexington, Massachusetts (PRWEB) August 06, 2013

Today, the FSH Society, a Massachusetts based non-profit that is a world leader in combating facioscapulohumeral dystrophy (FSHD), announced that it has awarded a $48,909 research grant to Dr. Jeffrey Statland, University of Rochester Fellow and Senior Instructor in the Department of Neurology. The grant will fund Dr. Statland’s evaluation of electrical impedance myography (EIM) as a tool for quantifying the muscle structure of FSHD patients. EIM offers a portable, quick and easy way to measure muscle changes in FSHD patients. The EIM tool was developed by Seward Rutkove, MD, and is manufactured by Convergence Medical Devices which is based in Boston, Massachusetts.

FSHD, one of the most prevalent types of muscular dystrophy, is a degenerative muscle disease that causes progressive weakness, usually starting with the face, shoulder and arms, but which can affect almost any skeletal muscle. FSHD affects approximately 500,000 people worldwide and between one and two percent of the population carries a genetic trait that places future generations at risk of the disease. Currently, there is no treatment.

“We are thrilled that the FSH Society continues supporting the development of new clinical outcomes for future FSHD clinical trials,” said Dr. Statland. “This is an exciting time for FSHD research. Recent breakthroughs in our understanding of the molecular pathology of FSHD identified future therapeutic targets – so developing efficient, high quality outcomes is a priority for the FSHD research community.”

While EIM technology is already commonly used in body composition measurement devices, it is considered a new tool for neuromuscular disorders. By applying this measurement technique to FSHD, clinicians could potentially identify muscle changes in patients before the muscles atrophy and weaken. EIM would also offer a way to document changes in muscles characteristically affected by FSHD which are not captured by traditional strength testing, such as facial muscles.

“This new study is an important step in the ongoing research around treatments and cures for FSHD,” said Daniel Paul Perez, President & CEO of the FSH Society “The grant will enable Dr. Statland and University of Rochester researchers to further develop their FSHD clinical trial tool-kit and expand current research efforts, bringing us closer to finding cost-effective treatments for FSHD.”

Dr. Statland and his team plan to recruit 20 participants with FSHD for four visits over 12 months of follow-up to test the reliability, validity and initial responsiveness to change of EIM in FSHD. They are seeking patients with genetic confirmation that are clinically affected by the disease and can walk. Patients with these qualifications that are interested in participating can contact Colleen Donlin-Smith at 585-275-7680 or Colleen_Donlin-Smith(at)urmc(dot)rochester(dot)edu.

The EIM pilot study will serve as a structural correlate for a FSHD observational study already underway at the University of Rochester Medical Center. Dr. Statland, in collaboration with Rabi Tawil, M.D. and experts at the Fields Center for FSHD and Neuromuscular Research University of Rochester Medical Center, received a prior grant of $55,597 for this study from the FSH Society in January 2013 to evaluate the reliability and concurrent validity of disease-specific patient reported outcome and evaluator administered functional rating scale.

# # #

About the FSH Society
The FSH Society, founded in 1991 by two FSHD patients, is a world leader in combating muscular dystrophy. The non-profit has provided millions of dollars in seed grants to pioneering research worldwide, creating an international collaborative network of patients and researchers. The FSH Society seeks to serve as a source of information and support for all patients and families with FSHD; act as a driving force in the development of research directed towards treatments and ultimately a cure; and bring support to patients and research for FSHD through effective engagement of governmental and private sector organizations and entities. For five consecutive years, the Society has received the Charity Navigator’s four-star rating, the highest distinction held by less than four percent of non-profit organizations in the country. The FSH Society offers a community of support, news and information for FSHD patients and families through its website at http://www.fshsociety.org. For further information about FSHD, please contact the Society at 781-301-6649.

Media Contact:
Victoria Khamsombath
SHIFT Communications
617-779-1828
FSHSociety(at)shiftcomm(dot)com

Read the full story at http://www.prweb.com/releases/2013/8/prweb10998990.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
3. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
4. Elsevier Collaborates with the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)
5. Monsanto Declared Worst Company of 2011 by NaturalSociety
6. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
7. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
8. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
9. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
10. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
11. Society of Interventional Radiology Names Marshall Hicks, M.D., FSIR, as 2012-13 President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016 Non-profit Consortium Aims to ... to Support Research and Discovery --> ... an ambitious plan to sequence 100,000 individuals. It is intended ... at least 7 of North and East Asian countries. ... phase, the project will focus on creating phased reference genomes ...
(Date:2/11/2016)... NEW YORK , Feb. 11, 2016  Bioethics International, ... how medicines are researched, developed, marketed and made accessible to ... BMJ Open had named the publication of the ... for 2015. The publication is also featured as one of ... published in the last year that are most frequently read. ...
(Date:2/11/2016)... Feb. 11, 2016  Dovetail Genomics™ LLC today announced ... program for a planned metagenomic genome assembly service. ... metagenomic genome assembly method in a talk on Friday, ... & Technology conference in Orlando, Fla. ... complex datasets is difficult. Using its proprietary ...
(Date:2/11/2016)... ... February 11, 2016 , ... Global Stem Cells Group, ... Bankok,Thailand-based Global Stem Cells Network (GSCN) to distribute exosome injection and other biological ... Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El Salvador, Venezuela, Peru, ...
Breaking Biology Technology:
(Date:2/10/2016)... India , February 10, 2016 /PRNewswire/ ... --> According to 2016 iris recognition ... identification iris recognition is more widely accepted ... available with both fingerprint and iris recognition ... the user to avoid purchasing two individual ...
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 /PRNewswire/ ... facilities are primarily focused on medical screening ... measure point-of-care parameters. Wearable devices that facilitate ... user,s freedom of movement are being bolstered ... for human biomedical signal acquisition coupled with ...
Breaking Biology News(10 mins):